Showing results (2741-2750 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|March 6, 2024
Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation statusAaron Shaykevich, Danbee Chae, Isaac Silverman, et al.
Investigational New Drugs|March 1, 2024
The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophagesPetra Henning, Anna Westerlund, Sofia Movérare-Skrtic, et al.
Investigational New Drugs|April 11, 2024
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjectsBei Cao, Tingting Ma, Yuqiang Zhang, et al.
Investigational New Drugs|February 17, 2024
Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancerLele Chang, Xuemei Zhang, Qian Ma, et al.
Investigational New Drugs|February 7, 2024
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trialAndrew J Armstrong, Ravit Geva, Hyun Cheol Chung, et al.
Investigational New Drugs|May 24, 2024
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participantsMichael J Hanley, Steven Zhang, Robert Griffin, et al.
Investigational New Drugs|May 22, 2024
Evolving or immutable - phase I solid tumor trials in the era of precision oncologyShannon S Stockton, G Dan Ayers, Cody Lee, et al.
Investigational New Drugs|May 3, 2024
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancerXinyi Liu, Zihan Guo, Lin Su, et al.
Investigational New Drugs|November 13, 2023
Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamideKelsey A Fletcher, Mai H Alkurashi, Andrew J Lindsay
Investigational New Drugs|September 14, 2024
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumorsNehal J Lakhani, Howard Burris, Wilson H Miller, et al.
Pageof 372